IDL Diagnostics (IDLDX) Q4 2024 earnings summary

Executive summary

• Revenue increased by 62% in Q4 year-over-year and by 33% for the full year compared to the previous year, marking the fourth consecutive year of sales growth.

• Achieved positive EBITDA and positive cash flow in Q4, signaling progress toward sustainable profitability.

• Strategic partnerships, notably with ZECEN and a leading Japanese IVD company, have strengthened market presence in China and are expected to drive future growth.

• Ongoing strategic review focused on growth and business development, supported by a strong cash position for potential in-licensing or acquisitions.

Financial highlights

• Q4 net sales: KSEK 15,364 (up from 9,511); full-year net sales: KSEK 57,436 (up from 43,039).

• Q4 profit after financial items: KSEK -8,997 (improved from -17,136); full-year: KSEK -42,449 (improved from -59,297).

• Q4 EBITDA: KSEK 964 (up from -5,940); full-year EBITDA: KSEK -323 (up from -14,184).

• Cash and cash equivalents at year-end: KSEK 47,785 (down from 50,723).

• Earnings per share for the year: SEK -0.18 (improved from -0.26).

Outlook and guidance

• Anticipates continued strong order intake and organic growth in existing and new markets, with a focus on Indonesia, Germany, and China.

• Expects increased sales volumes in China as TPS CLIA is adopted by more hospitals and additional products are registered.

• Confident in building on recent successes to achieve long-term, sustainable profitability in 2025.